UNSPSC 51293901: Oxabrexine

This classification denotes a mucolytic agent and antitussive agent with the molecular formula C18H25Br2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F220MU498K, chemically known as ethyl-((4,6-dibromo-alpha-(cyclohexylmethylamino)-o-tolyl)oxy)acetate but generally known as oxabrexine, which bears US NIH Compound Identifier 167463. European Medicines Agency schedules Oxabrexine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09482MIG.

UNSPSC 51293901 Oxabrexine is a Commodity code that encompasses pharmaceutical products, though state and local governments purchasing under this code are actually procuring a broader array of medications and health-related supplies including naloxone, generic pharmaceuticals, over-the-counter products, and drug deactivation systems. The issuing bodies are diverse and include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida, has solicited naloxone and drug deactivation systems for community health initiatives, while the Texas Health and Human Services Commission has explored direct-to-manufacturer prescription programs through a request for information, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) has established multi-vendor contracts for generic pharmaceuticals and OTC products across participating state and local facilities. The scope of work spans procurement of finished pharmaceutical units for distribution through county community health facilities, exploration of alternative pharmacy benefit models at the state level, and establishment of cooperative purchasing frameworks that distribute products through authorized wholesalers to multiple member jurisdictions.

Recent activity is concentrated in the Southwest and Upper Midwest. Seminole County's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually, posted June 30, 2026, with bids due July 26, 2023, represents county-level procurement with quarterly deliveries required to a single health facility. The Texas HHS Commission's RFI (HHS0017013), issued April 3, 2026, sought vendor capabilities for direct manufacturer prescription programs without a formal competitive timeline. The MMCAP RFP (S1070000015802), posted January 20, 2026, with proposals due March 26, 2026, represents cooperative purchasing across multiple states including Minnesota and Oregon, with awarded vendors supplying generic pharmaceuticals through three authorized wholesalers and contracts effective July 1, 2026. Cooperative purchasing vehicles dominate the landscape for larger pharmaceutical procurement, while county health systems pursue direct IFBs for specific therapeutics and harm-reduction supplies. Pricing and volume commitments vary significantly—MMCAP's multi-award structure emphasizes price competitiveness (weighted at 75 percent of evaluation) and compliance with cGMP and DSCSA, while county procurements focus on unit availability and logistics.